vs
Side-by-side financial comparison of Enovis CORP (ENOV) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($761.7M vs $589.2M, roughly 1.3× Enovis CORP). Insulet Corporation runs the higher net margin — 12.0% vs -1.4%, a 13.4% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 5.4%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 5.9%).
Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
ENOV vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $589.2M | $761.7M |
| Net Profit | $-8.4M | $91.1M |
| Gross Margin | 62.0% | 69.5% |
| Operating Margin | — | 16.0% |
| Net Margin | -1.4% | 12.0% |
| Revenue YoY | 5.4% | 33.9% |
| Net Profit YoY | — | 157.3% |
| EPS (diluted) | $-0.15 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $589.2M | $761.7M | ||
| Q4 25 | $548.9M | $783.7M | ||
| Q3 25 | $564.5M | $706.3M | ||
| Q2 25 | $558.8M | $649.1M | ||
| Q1 25 | — | $569.0M | ||
| Q4 24 | $561.0M | $597.5M | ||
| Q3 24 | $505.2M | $543.9M | ||
| Q2 24 | $525.2M | $488.5M |
| Q1 26 | $-8.4M | $91.1M | ||
| Q4 25 | $-571.1M | $101.6M | ||
| Q3 25 | $-36.7M | $87.6M | ||
| Q2 25 | $-56.0M | $22.5M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | $-703.2M | $100.7M | ||
| Q3 24 | $-31.5M | $77.5M | ||
| Q2 24 | $-18.6M | $188.6M |
| Q1 26 | 62.0% | 69.5% | ||
| Q4 25 | 59.9% | 72.6% | ||
| Q3 25 | 59.3% | 72.2% | ||
| Q2 25 | 59.5% | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | 54.8% | 72.1% | ||
| Q3 24 | 56.7% | 69.3% | ||
| Q2 24 | 55.0% | 67.7% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | -101.7% | 18.7% | ||
| Q3 25 | -3.0% | 16.7% | ||
| Q2 25 | -8.4% | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | -118.5% | 18.3% | ||
| Q3 24 | -6.3% | 16.2% | ||
| Q2 24 | -8.4% | 11.2% |
| Q1 26 | -1.4% | 12.0% | ||
| Q4 25 | -104.1% | 13.0% | ||
| Q3 25 | -6.5% | 12.4% | ||
| Q2 25 | -10.0% | 3.5% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | -125.4% | 16.9% | ||
| Q3 24 | -6.2% | 14.2% | ||
| Q2 24 | -3.5% | 38.6% |
| Q1 26 | $-0.15 | $1.30 | ||
| Q4 25 | $-9.99 | $1.42 | ||
| Q3 25 | $-0.64 | $1.24 | ||
| Q2 25 | $-0.98 | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | $-12.69 | $1.38 | ||
| Q3 24 | $-0.58 | $1.08 | ||
| Q2 24 | $-0.34 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.1M | $480.4M |
| Total DebtLower is stronger | $1.3B | $18.6M |
| Stockholders' EquityBook value | $1.5B | $1.3B |
| Total Assets | $3.8B | $3.0B |
| Debt / EquityLower = less leverage | 0.90× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $33.1M | $480.4M | ||
| Q4 25 | $33.6M | — | ||
| Q3 25 | $44.1M | — | ||
| Q2 25 | $38.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $48.2M | — | ||
| Q3 24 | $35.4M | — | ||
| Q2 24 | $35.0M | — |
| Q1 26 | $1.3B | $18.6M | ||
| Q4 25 | $1.4B | $930.8M | ||
| Q3 25 | $1.4B | $934.9M | ||
| Q2 25 | $1.4B | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $1.3B | $1.4B |
| Q1 26 | $1.5B | $1.3B | ||
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.6B | $1.5B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $2.6B | $1.2B | ||
| Q3 24 | $3.3B | $1.1B | ||
| Q2 24 | $3.3B | $998.4M |
| Q1 26 | $3.8B | $3.0B | ||
| Q4 25 | $4.4B | $3.2B | ||
| Q3 25 | $5.0B | $3.0B | ||
| Q2 25 | $4.9B | $3.5B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | $4.7B | $3.1B | ||
| Q3 24 | $5.6B | $3.0B | ||
| Q2 24 | $5.4B | $2.9B |
| Q1 26 | 0.90× | 0.01× | ||
| Q4 25 | 0.67× | 0.61× | ||
| Q3 25 | 0.54× | 0.68× | ||
| Q2 25 | 0.53× | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | 0.52× | 1.07× | ||
| Q3 24 | 0.40× | 1.21× | ||
| Q2 24 | 0.41× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $113.8M |
| Free Cash FlowOCF − Capex | — | $89.5M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | — | 3.2% |
| Cash ConversionOCF / Net Profit | — | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $82.6M | $183.3M | ||
| Q3 25 | $47.8M | $125.7M | ||
| Q2 25 | $-1.6M | $196.5M | ||
| Q1 25 | — | $63.8M | ||
| Q4 24 | $88.3M | $147.7M | ||
| Q3 24 | $53.6M | $98.5M | ||
| Q2 24 | $7.8M | $96.5M |
| Q1 26 | — | $89.5M | ||
| Q4 25 | $29.1M | $48.2M | ||
| Q3 25 | $3.4M | $100.1M | ||
| Q2 25 | $-44.9M | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | $35.1M | $94.1M | ||
| Q3 24 | $2.4M | $71.8M | ||
| Q2 24 | $-31.6M | $74.0M |
| Q1 26 | — | 11.8% | ||
| Q4 25 | 5.3% | 6.2% | ||
| Q3 25 | 0.6% | 14.2% | ||
| Q2 25 | -8.0% | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | 6.3% | 15.7% | ||
| Q3 24 | 0.5% | 13.2% | ||
| Q2 24 | -6.0% | 15.1% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 9.7% | 17.2% | ||
| Q3 25 | 7.9% | 3.6% | ||
| Q2 25 | 7.7% | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 9.5% | 9.0% | ||
| Q3 24 | 10.1% | 4.9% | ||
| Q2 24 | 7.5% | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENOV
Segment breakdown not available.
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
